AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients

Atopic dermatitis, commonly known as eczema, is a long-term condition that causes dry, red, and itchy skin. This clinical trial is looking at a new potential treatment known as PF-07832837. This is a Phase 1 study, which means it is one of the first times this medicine is being tested in humans. The main goal is to find out how safe different doses are, what side effects might happen, and how the body processes the drug. The trial will involve both healthy volunteers and people with eczema. Doctors and nurses will closely monitor everyone who takes part. They will check vital signs, take blood samples, and track participants' health throughout the study. Taking part is completely voluntary. It will not affect your standard NHS healthcare, and you can change your mind and stop at any time.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

Pfizer Inc.

Enrolment target

Start

18 Jun 2026

Atopic Dermatitis

What is this study about?

Atopic dermatitis, often called atopic eczema, affects millions of people across the UK. It causes the skin to become dry, cracked, sore, and intensely itchy. While existing treatments like moisturisers, steroid creams, and light therapy help many people, they do not work well for everyone. Because of this, scientists are continually working to develop new, more effective therapies.

This clinical study focuses on an experimental medicine currently named PF-07832837. It is a 'Phase 1' trial, which is an important early step in medical research. Before any new treatment can be widely tested to see how well it heals skin, doctors must first check that it is safe to take and understand how it moves through the bloodstream and organs.

During the trial, researchers will test different amounts (doses) of PF-07832837 in small groups of people. They want to learn how well the human body tolerates the medicine and what dose might be best for future research. By taking part, volunteers provide essential information that helps researchers decide whether this medicine could become a future treatment for eczema.

Key takeaways

Tests an experimental drug called PF-07832837 for atopic dermatitis (eczema).
Focuses on safety, tolerability, and how the drug moves through the body.
Open to both healthy adults and people with eczema aged 18 and older.
Early-stage (Phase 1) trial with close medical supervision at all times.
Participation is entirely voluntary, and you can leave at any time.

Who may be eligible?

This trial is open to adults aged 18 and over, including both men and women. Because this is an early safety study, the researchers are looking for two groups of people: healthy adult volunteers, and adults who have been diagnosed with atopic dermatitis (eczema).

To make sure taking part is as safe as possible, there are clear rules about who can join. You will need to undergo medical checks, which may include blood tests and heart traces, to confirm that you are well enough to participate.

You might not be able to join if you have certain other major medical conditions, if you take medicines that could interact with the study drug, or if you are pregnant or breastfeeding. The trial team will review your full medical history before you start.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

You are aged 18 or older.
You are either in good general health or have a diagnosis of atopic dermatitis (eczema).
You are able to travel to the study clinic for appointments and tests.
You are not currently pregnant or breastfeeding.
You are happy to have routine health checks, such as blood tests and heart traces.

Answer every question to see your result.

What does participation involve?

Taking part begins with a screening appointment at a specialist clinic where doctors will explain the study and check your general health. If you are eligible and agree to join, you will be given the study medicine, PF-07832837. Depending on the trial plan, you may need to stay in the clinic for a short period or visit regularly as an outpatient. During your visits, the research team will monitor your blood pressure, heart rate, and temperature, and take routine blood and urine samples to see how the medicine acts in your body. You will also have follow-up visits so doctors can check that you have fully recovered and remain well. The trial team will confirm the exact schedule and total length of time before you agree to take part.

Potential risks and benefits

Because this is an early-stage safety study, taking part may not directly improve your eczema symptoms, especially if you join as a healthy volunteer. As with any new medicine, there is a risk of unexpected side effects or allergic reactions. However, your health and safety will be monitored very closely by experienced medical staff throughout the study. Your participation helps doctors learn more about the drug, which could help people with eczema in the future. Joining is entirely your choice, and you are free to withdraw from the trial at any point without giving a reason and without your normal NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Poland

Common questions

What is PF-07832837?

PF-07832837 is the research code name for an experimental drug being developed to see if it could help treat atopic dermatitis (eczema).

What does a Phase 1 study mean?

A Phase 1 study is an early research stage where a medicine is tested in a small group of people to check its safety, side effects, and how the body handles it.

Why are healthy people included in an eczema study?

Testing a medicine in healthy volunteers first helps doctors see how it behaves in a normal body system without the influence of other health issues or treatments.

Will I be paid for taking part?

Phase 1 trials often provide payment to compensate participants for their time, travel, and commitment. The research clinic can provide details on this.

Can I leave the trial if I change my mind?

Yes. Taking part is completely voluntary. You can stop participating at any time, and it will not affect your standard medical care.